SEATTLE & CAMBRIDGE, Mass. & TOKYO, March 28, 2024--Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Canada , Tokyo , Japan , United States , Canadian , Michele Gray , Judith Mcgarry , Michael Goldstein , Prix Galien , Beth Keshishian , Allogeneic Cell Therapy , Corneal Edema Secondary , Corneal Endothelial , Aurion Biotech , Chief Medical Officer , Flyingl Partners , Falcon Vision ,